Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex

Biological Psychiatry

Volumn 50, Issue 10, 2001, Pages 750-757

  Adams, Barbara W ^a   Moghaddam, Bita ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic drugs; Ketamine; Microdialysis; Schizophrenia; Serotonin

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPA RECEPTOR ANTAGONIST; CLOZAPINE; GLUTAMIC ACID; HALOPERIDOL; KETAMINE; METABOTROPIC RECEPTOR AGONIST; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; EFFUSION; LOCOMOTION; MALE; MICRODIALYSIS; NONHUMAN; PREDICTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; STEREOTYPY; SYMPTOM;

ANIMALS; CLOZAPINE; FLUOROBENZENES; GLUTAMIC ACID; HALOPERIDOL; MALE; MICRODIALYSIS; PHENCYCLIDINE; PIPERIDINES; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN ANTAGONISTS;

EID: 0035890695     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(01)01195-7     Document Type: Article

References (59)

1. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine
2. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers
3. 2A receptors increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release
4. Serotonin model of schizophrenia: Emerging role of glutamate mechanisms
5. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists
6. Phencyclidine (PCP): A review and perspectives
7. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response
8. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers
9. Behavioral and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats
10. Perspectives: Acute phencyclidine intoxication
11. Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex
12. Antipsychotic drugs, neurotransmitters, and schizophrenia
13. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats
14. Effects of dopaminergic drugs on phencyclidine-induced behavior in the rat
15. Effects of atypical antipsychotic agents on social behavior in rodents
16. Animal models of negative symptoms: M100907 antagonizes PCP induced immobility in a forced swim test in mice
17. The glutamatergic dysfunction hypothesis for schizophrenia
18. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats
19. Comparison of the effects of clozapine, risperidone and olanzapine on ketamine-induced alterations in regional brain metabolism
20. Assessing prepulse inhibition of startle in wild-type and knockout mice
21. The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801
22. Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study
23. Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats
24. Recent advances in the phencyclidine model of schizophrenia
25. Excitatory amino acid receptors mediate the orofacial stereotypy elicited by dopaminergic stimulation of the ventrolateral striatum
26. Effects of risperidone on phencyclidine-induced behaviors: Comparison with haloperidol and ritanserin
27. Modulation of phencyclidine-induced changes in locomotor activity and patterns in rats by serotonin
28. Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists
29. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans
30. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
31. Ketamine activates psychosis and alters limbic blood flow in schizophrenia
32. Regulation of glutamate efflux by excitatory amino acid receptors: Evidence for tonic inhibitory and phasic excitatory regulation
33. Study of a new schizophrenomimetic drug-sernyl
34. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine
35. The electrophysiology of prefrontal serotonin systems: Therapeutic implications for mood and psychosis
36. Systemic PCP treatment elevates brain extracellular 5-HT: A microdialysis study in awake rats
37. MK-801-induced hyperlocomotion: Differential effects of M100907, SDZ PSD958 and raclopride
38. Non-NMDA excitatory amino acid receptors in the ventral-tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens
39. Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100, 907 in rats reflects antagonism of 5-HT2A receptors
40. Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia
41. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
42. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
43. Phencyclidine and dizocilpine-induced hyperlocomotion are differentially mediated
44. Excitotoxic amino acids and neuropsychiatric disorders
45. Glutamate receptor dysfunction and schizophrenia
46. Effects of 5-hydroxytryptamine2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine
47. Effects of continuous d-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity
48. Regional effects of MK-801 on dopamine release: Effects of competitive NMDA or 5-HT2A receptor blockade
49. The effects of haloperidol and clozapine on PCP and amphetamine induced suppression of social behavior
50. Crucial role of the accumbens nucleus in the neurotransmitter interactions regulating motor control in mice
51. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs
52. Target specific glutamatergic regulation of dopamine neurons in the ventral tegmental area
53. Schizophrenia and glutamatergic transmission
54. Brain microdialysis of GABA and glutamate: What does it signify?
55. M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats
56. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: Modulation by dopamine
57. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice
58. Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats